FDA Approves Brenzavvy for People with Type 2 Diabetes

      Big news in the world of diabetes care! The US Food and Drug Administration (FDA) has recently given the green light to a new medication called bexagliflozin (brand name Brenzavvy) by TheracosBio. This approval marks a significant advancement in the treatment options available for adults with type 2 diabetes.

      Brenzavvy is a once-a-day oral medication, specifically an SGLT2 inhibitor. This type of drug works by influencing the kidneys to remove excess glucose from the body through urine, thus helping to manage blood glucose levels.

      This medication is designed for adults with type 2 diabetes as part of a broader treatment plan that includes diet and exercise. However, it's not suitable for people with type 1 diabetes. It's also important to note that Brenzavvy can be used by patients who have a kidney function above a certain level (an eGFR greater than 30 mL/min/1.73m²).

      The FDA’s approval is based on the results from the phase 3 Bexagliflozin Efficacy and Safety Trial (BEST). In this study, Brenzavvy not only met its targets for effectiveness in controlling blood sugar levels but also passed safety checks, especially for patients at high risk of cardiovascular problems.

      With the approval of Brenzavvy, there's now an additional treatment option for those managing type 2 diabetes. It's especially significant for patients looking for effective blood sugar management alongside a reduced risk of cardiovascular issues.